ArticleJournal of the National Cancer Institute. Monographs2022
Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
Article in Journal of the National Cancer Institute. Monographs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.The New England journal of medicine · 2024Trial
- Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.Gynecologic oncology · 2023Trial
- Comparison of geriatric assessment with provider's clinical assessment among older adults with gastroesophageal cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Review
- Predictors of Clinical Trial Participation Among Older U.S. Adults With Multimorbidity: A Cross-Sectional Survey.Clinical and translational science · 2026Article
- Embracing the Digital Revolution: How Artificial Intelligence is Transforming Clinical Trials in Older Participants.Drugs & aging · 2026Review
- Preferences Regarding Clinical Drug Trial Elements: A Nationally Representative Survey of Older Adults With Multimorbidity.Journal of the American Geriatrics Society · 2025Article
- Article
- Patterns of presentation, treatment, and survival among older adults with metastatic breast cancer: Results from a large prospective registry.Journal of geriatric oncology · 2025Article
- Navigating the Path to Inclusion: Understanding Barriers and Facilitators to Clinical Trial Participation Among Chinese Older Adults in the United States with Multimorbidity.Journal of general internal medicine · 2025Article
- Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes.Journal of the National Cancer Institute · 2024Article
- Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer's-type dementia therapies.Alzheimer's research & therapy · 2024Review
- Comorbid Dementia and Cancer Therapy Decision-Making: A Scoping Review.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2024Article
- Attitudes on participation in clinical drug trials: A nationally representative survey of older adults with multimorbidity.Journal of the American Geriatrics Society · 2024Article
- Aging and cancer.Molecular cancer · 2024Review
- Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer:JACC. CardioOncology · 2024Review
- Disparities in care of older adults of color with cancer: A narrative review.Cancer medicine · 2024Review
- Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 12 institutions in 2 countries.
Funding
Abstract
Although adults aged 65 years or older make up a strong majority of cancer patients, their underrepresentation in cancer clinical trials leads to the lack of representative data to guide evidence-based therapeutic decisions in this patient population. The Trial Design Working Group, convened as part of the workshop titled, Engaging Older Adults in the National Cancer Institute Clinical Trials Network: Challenges and Opportunities, recommended study designs and design elements that could improve accrual of older adults in National Cancer Institute-funded clinical trials. These include trials that are specifically designed to enroll older adults, trials that include a cohort of older patients (parallel cohort, stratified cohort, or embedded cohort), and trials with pragmatic design elements to facilitate enrollment of older adults. This manuscript provides brief descriptions of the recommended designs, examples of successful trials, and considerations for implementation of these designs. As with any clinical trial, the scientific questions and trial objectives should drive the study design, the selection of endpoints and intervention, and eligibility criteria. When designing trials that include older adults, the heterogeneity of fitness levels is an important consideration as fitness can influence accrual rates and outcomes. Appropriately incorporating geriatric assessments can help identify the optimal subset of older patients for inclusion and minimize selection bias. Incorporating pragmatic design elements to reduce the burden on trial participants as well as on accruing sites and retaining essential elements to ensure that the main goal of the trial can be accomplished can enhance enrollment without compromising the integrity of trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.